Correlation of serum adenosine deaminase activity with disease activity in patients with primary Sjögren's syndrome.

[1]  Lijun Wu,et al.  Hyperglobulinemia predicts increased risk of mortality in primary Sjögren's syndrome: based on a Chinese multicentre registry. , 2023, Modern rheumatology.

[2]  Teng Zhang,et al.  The immunomodulatory function of adenosine in sepsis , 2022, Frontiers in Immunology.

[3]  E. Oleinik,et al.  Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer , 2022, Biomolecules.

[4]  Han Shen,et al.  Increased serum adenosine deaminase activity in patients with adult-onset Still's disease , 2022, BMC immunology.

[5]  K. Baumgart,et al.  Candidate autoantibodies for primary Sjögren's syndrome: where are they now? , 2021, Clinical and experimental rheumatology.

[6]  X. Mariette,et al.  Current and future therapies for primary Sjögren syndrome , 2021, Nature Reviews Rheumatology.

[7]  S. Negrini,et al.  Sjögren’s syndrome: a systemic autoimmune disease , 2021, Clinical and Experimental Medicine.

[8]  G. Norata,et al.  HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases , 2021, Cells.

[9]  K. Dong,et al.  The roles of adenosine deaminase in autoimmune diseases. , 2020, Autoimmunity reviews.

[10]  E. Latz,et al.  High-Density Lipoproteins Decrease Proinflammatory Activity and Modulate the Innate Immune Response. , 2019, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[11]  I. Meyts,et al.  Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment , 2018, Journal of Clinical Immunology.

[12]  M. Garcia-Gil,et al.  The Inside Story of Adenosine , 2018, International journal of molecular sciences.

[13]  M. Kakei,et al.  High-density lipoprotein and apolipoprotein A-I inhibit palmitate-induced translocation of toll-like receptor 4 into lipid rafts and inflammatory cytokines in 3T3-L1 adipocytes. , 2017, Biochemical and biophysical research communications.

[14]  A. Zavialov,et al.  Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells , 2017, Cellular and Molecular Life Sciences.

[15]  K. Dong,et al.  The role of adenosinergic pathway in human autoimmune diseases , 2016, Immunologic research.

[16]  J. Parks,et al.  New roles of HDL in inflammation and hematopoiesis. , 2012, Annual review of nutrition.

[17]  F. Da Settimo,et al.  Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. , 2012, Current drug targets.

[18]  R. Krenke,et al.  [Role of biomarkers in making the diagnosis of tuberculous pleurisy]. , 2011, Pneumonologia i alergologia polska.

[19]  C. Gabay,et al.  Serum lipoproteins attenuate macrophage activation and Toll-Like Receptor stimulation by bacterial lipoproteins , 2010, BMC Immunology.

[20]  R. Krenke,et al.  Use of pleural fluid levels of adenosine deaminase and interferon gamma in the diagnosis of tuberculous pleuritis , 2010, Current opinion in pulmonary medicine.

[21]  T. Palmer,et al.  Suppression of inflammatory and immune responses by the A2A adenosine receptor: an introduction , 2008, British journal of pharmacology.

[22]  S. Bombardieri,et al.  Sjögren's Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. , 2007, Arthritis and rheumatism.

[23]  G. Cristalli,et al.  Adenosine deaminase: Functional implications and different classes of inhibitors , 2001, Medicinal research reviews.

[24]  F. Marumo,et al.  Adenosine deaminase isoenzymes in liver disease. , 1993, The American journal of gastroenterology.

[25]  M. Weyden,et al.  Human adenosine deaminase. Distribution and properties. , 1976, The Journal of biological chemistry.

[26]  Gholamreza Sharifzadeh,et al.  Hematologic parameters and disease activity in patients with primary Sjögren's syndrome , 2022, The Egyptian Rheumatologist.